NCT03435874View on ClinicalTrials.gov

Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

July 11, 2019

Study Completion Date

July 11, 2019

Conditions

Malaria,Falciparum

Interventions

BIOLOGICAL

ChAd63 RH5

Vaccine

BIOLOGICAL

MVA RH5

Vaccine

BIOLOGICAL

Rabies Vaccine

Vaccine

Trial Locations (1)

Unknown

Ifakara Health Institute Clinical Trial Facility, Bagamoyo

Sponsors

Collaborators (1)

Medical Research Council

All Listed Sponsors

collaborator

Ifakara Health Institute

OTHER

collaborator

Medical Research Council

OTHER_GOV

lead

University of Oxford

OTHER